Amicus Therapeutics
   
contact us sitemap
 
 

Insider Stock Ownership

Name Relationship / Title Current Shares Trading Activity
barer sol j Director 20,000 View
barkas alexander e Director 2,213,474 View
barris peter j Beneficial Owner (10% or more) 851,183 View
bloch stephen m Director 61,700 View
canaan equity partners iii llc Beneficial Owner (10% or more) 2,050,790 View
chl medical partners ii side fund, l.p. Beneficial Owner (10% or more) 4,084,011 View
chl medical partners ii, l.p. Beneficial Owner (10% or more) 4,084,010 View
crowley john f Officer 76,834 View
dentzer james e Officer 32,075 View
fhm iv lp Beneficial Owner (10% or more) 920,664 View
garden state life sciences venture fund l p Beneficial Owner (10% or more) 2,484,584 View
kramlich c richard Beneficial Owner (10% or more) 851,183 View
licholai gregory p Officer 152 View
mount sinai school of medicine of new york university Beneficial Owner (10% or more) 365,599 View
neff p sherrill Director 1,419,762 View
new enterprise associates 11 lp Beneficial Owner (10% or more) 3,650,488 View
newhall charles w iii Beneficial Owner (10% or more) 851,183 View
palling david Officer 34,040 View
patterson matthew r Officer 56,547 View
perry mark w Beneficial Owner (10% or more) 851,183 View
prospect venture partners ii lp Beneficial Owner (10% or more) 2,213,474 View
quaker bio ventures lp Beneficial Owner (10% or more) 2,484,584 View
sblendorio glenn Director 12,933 View
schaeffer orlov s nicole Officer 12,582 View
topper james n Director 920,664 View
weinhoff gregory m Director 129,943 View

Stock transaction information provided by EDGAR Online. Amicus Therapeutics makes no representation or warranty with respect any of to the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.